Chinese coronavirus-vaccine maker Sinovac Biotech is good at getting its products to market. It was first to begin clinical trials of a SARS vaccine in 2003 and first to bring a swine flu vaccine to consumers in 2009.
Its CEO was also bribing China’s drug regulator for vaccine approvals during that time, court records show.
Sinovac is now seeking to supply its coronavirus vaccine to developing nations, from Brazil to Turkey to Indonesia. While graft and weak transparency have long plagued China’s pharmaceutical industry, seldom has the reliability of a single drug vendor from the country mattered this much to the rest of the world…
Sinovac’s vaccine, Coronavac, may end up adopted in a number of developing markets. Officials in Brazil and Indonesia — the most populous nations in Latin America and Southeast Asia — say Coronavac could be approved in coming weeks. In Brazil, São Paulo Gov. João Doria has called it the safest vaccine the country has tested.
Join the conversation as a VIP Member